State Street Corp Has $23.09 Million Position in Cytek Biosciences, Inc. (NASDAQ:CTKB)

State Street Corp grew its holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 4.9% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,167,501 shares of the company's stock after acquiring an additional 194,369 shares during the period. State Street Corp owned 3.24% of Cytek Biosciences worth $23,088,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. SlateStone Wealth LLC bought a new stake in Cytek Biosciences in the second quarter worth $70,000. Olympiad Research LP bought a new stake in shares of Cytek Biosciences during the 3rd quarter worth about $72,000. Everence Capital Management Inc. increased its holdings in shares of Cytek Biosciences by 20.9% during the 3rd quarter. Everence Capital Management Inc. now owns 16,760 shares of the company's stock valued at $93,000 after acquiring an additional 2,900 shares during the last quarter. Dark Forest Capital Management LP raised its stake in shares of Cytek Biosciences by 85.3% in the 2nd quarter. Dark Forest Capital Management LP now owns 21,098 shares of the company's stock valued at $118,000 after acquiring an additional 9,711 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new stake in Cytek Biosciences in the 3rd quarter worth approximately $128,000. Institutional investors and hedge funds own 69.46% of the company's stock.

Analyst Ratings Changes

Separately, Piper Sandler increased their price target on Cytek Biosciences from $8.00 to $8.50 and gave the company an "overweight" rating in a report on Monday, November 11th.

Cytek Biosciences Trading Up 2.2 %

Cytek Biosciences stock traded up $0.14 on Monday, reaching $6.46. 360,115 shares of the stock were exchanged, compared to its average volume of 690,343. Cytek Biosciences, Inc. has a twelve month low of $4.66 and a twelve month high of $9.87. The firm has a fifty day moving average price of $6.06 and a two-hundred day moving average price of $5.78. The stock has a market cap of $832.12 million, a PE ratio of -80.74 and a beta of 1.46.

Cytek Biosciences (NASDAQ:CTKB - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.03. The business had revenue of $51.50 million during the quarter, compared to analysts' expectations of $50.63 million. Cytek Biosciences had a negative return on equity of 2.58% and a negative net margin of 5.05%. During the same quarter in the previous year, the firm earned ($0.03) EPS. Equities analysts anticipate that Cytek Biosciences, Inc. will post -0.06 EPS for the current fiscal year.

Cytek Biosciences Company Profile

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.